Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations.
Ciano-Petersen NL, Aliaga-Gaspar P, Hurtado-Guerrero I, Reyes V, Rodriguez-Bada JL, Rodriguez-Traver E, Brichette-Mieg I, Leyva Fernández L, Serrano-Castro P, Alonso A, Oliver-Martos B. Ciano-Petersen NL, et al. Among authors: oliver martos b. Front Immunol. 2023 Aug 22;14:1242508. doi: 10.3389/fimmu.2023.1242508. eCollection 2023. Front Immunol. 2023. PMID: 37675113 Free PMC article.
Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment.
Aliaga-Gaspar P, Hurtado-Guerrero I, Ciano-Petersen NL, Urbaneja P, Brichette-Mieg I, Reyes V, Rodriguez-Bada JL, Alvarez-Lafuente R, Arroyo R, Quintana E, Ramió-Torrentà L, Alonso A, Leyva L, Fernández O, Oliver-Martos B. Aliaga-Gaspar P, et al. Among authors: oliver martos b. Front Immunol. 2021 Dec 16;12:778204. doi: 10.3389/fimmu.2021.778204. eCollection 2021. Front Immunol. 2021. PMID: 34975865 Free PMC article.
Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNß in Multiple Sclerosis Patients According to the Therapeutic Response to IFNß.
Hurtado-Guerrero I, Pinto-Medel MJ, Urbaneja P, Rodriguez-Bada JL, León A, Guerrero M, Fernández Ó, Leyva L, Oliver-Martos B. Hurtado-Guerrero I, et al. PLoS One. 2017 Jan 19;12(1):e0170031. doi: 10.1371/journal.pone.0170031. eCollection 2017. PLoS One. 2017. PMID: 28103257 Free PMC article.
Current Status of Biomarkers in Anti-N-Methyl-D-Aspartate Receptor Encephalitis.
Ciano-Petersen NL, Cabezudo-García P, Muñiz-Castrillo S, Honnorat J, Serrano-Castro PJ, Oliver-Martos B. Ciano-Petersen NL, et al. Among authors: oliver martos b. Int J Mol Sci. 2021 Dec 4;22(23):13127. doi: 10.3390/ijms222313127. Int J Mol Sci. 2021. PMID: 34884930 Free PMC article. Review.
Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker.
Órpez-Zafra T, Pavía J, Hurtado-Guerrero I, Pinto-Medel MJ, Rodriguez Bada JL, Urbaneja P, Suardíaz M, Villar LM, Comabella M, Montalban X, Alvarez-Cermeño JC, Leyva L, Fernández Ó, Oliver-Martos B. Órpez-Zafra T, et al. Mult Scler. 2017 Jun;23(7):937-945. doi: 10.1177/1352458516667564. Epub 2016 Sep 9. Mult Scler. 2017. PMID: 27613121
Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis.
Ciano-Petersen NL, Robert M, Muñiz-Castrillo S, Wucher V, Klich A, Vogrig A, Villagrán García M, Farina A, Goncalves D, Picard G, Rogemond V, Joubert B, Oliver-Martos B, Serrano-Castro PJ, Maucort-Boulch D, Honnorat J. Ciano-Petersen NL, et al. Among authors: oliver martos b. Neurol Neuroimmunol Neuroinflamm. 2023 May 5;10(4):e200108. doi: 10.1212/NXI.0000000000200108. Print 2023 Jul. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37147137 Free PMC article.
33 results